Presentation Title: A non-biologic nanoparticle paclitaxel (NBN-Pac) formulation (IG-001) with characteristics of albumin-based formulation-(
Dr. Hwang will present consolidated phase I data and tumor accumulation data for IG-001 of our phase III-pready drug candidate, IG-001, a chemical polymer-bound nanoparticle paclitaxel. The data were accumulated through a development program across five major cancer indications:
Clinical studies of IG-001 performed in the United States and other countries such as Korea and Russia, have demonstrated similar clinical activity as albumin-bound paclitaxel (Abraxane®) in patients with metastatic breast cancer, non-small cell lung cancer, advanced pancreatic cancer and ovarian cancer. IG-001 is currently approved and commercially available in Korea as Genexol PM®. These properties make IG-001 an ideal platform for personalized paclitaxel; where personalized dosing and patient selection are combined with the best paclitaxel nanoparticle formulation to potentially achieve safe and effective paclitaxel chemotherapy.
About AACR Special Conference on Tumor Invasion and Metastasis (2013):
Tumor metastasis is the principle cause of mortality among cancer patients. Much of the progress in the metastasis field has been made in understanding the process of tumor dissemination – the steps between growth of the primary tumor and establishment of the secondary tumors. Increasingly, however, it is recognized that we need to have a better understanding of established metastases as it is only by antagonizing the growth of these tumors that we will be able to help patients with aggressive metastatic disease. The field has benefited from improvements of real-time imaging of processes such as extravasation, intravasation, circulating tumor cells and dormant metastases. Advances in the metastasis field have also had a singular impact on the biomarker field, especially aiding the discovery of markers for the prediction of patient outcome.
This conference will address all aspects of tumor metastasis through presentations from scientific experts performing innovative research in basic, translational and clinical science. In addition to scientific talks from distinguished scientists and short proffered talks from early-career scientists, this conference will also feature a special forum with a panel discussion session on “Cancer Stem Cells and Metastasis.”
IGDRASOL is a developer of personalized nanoparticle paclitaxel therapy. At IGDRASOL, we are taking advantage of the convergence of technologies that make personalized paclitaxel therapy possible. Our platform is IG-001 (chemical polymer-bound nanoparticle paclitaxel), a next generation nanoparticle paclitaxel with clinical activity demonstrated to date to be at least on par with Abraxane. IG-001 is free of issues with Cremophor and albumin; excipients for Taxol® (Cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. It combines the manufacturing simplicity of Taxol with the albumin-mediated transport properties of Abraxane. IGDRASOL will be conducting registration trials for multiple cancer indications.
IG-001(chemical polymer-bound nanoparticle paclitaxel) is approved in Korea and marketed by Samyang Biopharmaceuticals as Genexol-PM®. IGDRASOL, together with its corporate partners, are also developing quantitative point-of-care testing solutions for biomarker testing and paclitaxel therapeutic drug monitoring—technologies which would be instrumental in personalizing paclitaxel therapy. The executives of IGDRASOL are a group of pharmaceutical veterans who believe that personalized nanoparticle paclitaxel therapy will present a paradigm shift in the delivery of chemotherapeutic agents. To learn more about our mission please visit our website (http://www.igdrasol.com).
Genexol PM® is a registered trademark of Samyang Corporation. Abraxane® is a registered trademark of Celgene, Inc. Taxol® is a registered trademark of Bristol-Myers Squibb, Inc.
Vuong Trieu, Ph.D.
Chief Executive Officer
Forward-Looking Statements :
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. These statements are based on management's current beliefs and expectations and our business is subject to numerous risks and uncertainties. Some of the risks include that we have a limited operating history and limited financial resources, that our product candidates have not completed clinical development and have not received and may not ever receive regulatory approval for commercialization. As a result of risks affecting our business, actual results or events could differ materially from the plans, projections and expectations set forth in our forward-looking statements, therefore, readers are cautioned not to place undue reliance on such forward-looking statements. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this presentation except as required by law.